ClinicalTrials.gg
CompletedNCT00144989Updated Sep 22, 2016

A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

A Phase 3 interventional study of Etoposide and cisplatin after chemoradiotherapy and Irinotecan and cisplatin after chemoradiotherapy in Small-Cell-Lung Cancer, sponsored by Haruhiko Fukuda. Completed at 37 sites in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Haruhiko Fukuda · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Small Cell Lung Carcinoma with a site in Japan — 27 open to participants now, 44 under way, 18 of them phase 3. Small Cell Lung Carcinoma · Japan.

Enrollment
34th of 76
281 · median 240
Started
2002
the only one that year
Phase 3
26 of 78
9 open now
Registered
2nd of 78
by date

Among the 78 studies in Small Cell Lung Carcinoma with a site in Japan, this one is the 34th largest by enrollment of the 76 interventional ones that give a count, is the only one that started in 2002, is one of 26 in phase 3, and was the 2nd registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

27 of the 78 studies in Small Cell Lung Carcinoma with a site in Japan are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Small Cell Lung Carcinoma with a site in Japan, or all of them as a file.
02

Study summary

To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.

Read the detailed description

The Japan Clinical Oncology Group (JCOG) previously conducted a randomized phase III trial comparing irinotecan and cisplatin (IP) with EP in patients with extensive-stage SCLC. The response rate and overall median survival were significantly better for IP, i.e. 84.4% and 12.8 months with IP, versus 67.5% and 9.4 months with EP, respectively. The 2-year survival rates were 19.5% for IP and 5.2% for EP (7). These encouraging results prompted us to explore the use of IP in LSCLC.

03

Conditions studied

  • Small-Cell-Lung Cancer

Keywords

  • Small-cell lung cancer
  • Limited-Stage Small-Cell Lung Cancer
  • Combined modality therapy
  • chemotherapy
  • radiotherapy
  • Irinotecan
  • Cisplatin
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. cytologically, proven small-cell lung cancer
  2. limited disease
  3. age 20-70 years old
  4. performance status of 0-1
  5. no prior treatment for small-cell lung cancer
  6. no history of chemotherapy
  7. adequate organ functions
  8. written

Exclusion criteria

Exclusion Criteria:

  1. pericardial effusion
  2. active concomitant
  3. pregnant or lactating women
  4. interstitial pneumonia/active lung fibrosis on chest x-ray, watery diarrhea, intestinal obstruction or paralysis, uncontrolled heart disease or a history of myocardial infarction within the previous 6 months, uncontrolled diabetes mellitus, active infection, psychological disease deemed unacceptable for inclusion to the study, long-term treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
281 participants (actual)

Study arms

  • Active comparator
    1

    Etoposide and cisplatin after chemoradiotherapy

    Drug: Etoposide and cisplatin after chemoradiotherapy

  • Experimental
    2

    Irinotecan and cisplatin after chemoradiotherapy

    Drug: Irinotecan and cisplatin after chemoradiotherapy

Interventions

  • DrugEtoposide and cisplatin after chemoradiotherapy

    Etoposide and cisplatin after chemoradiotherapy

  • DrugIrinotecan and cisplatin after chemoradiotherapy

    Irinotecan and cisplatin after chemoradiotherapy

06

What researchers measure

Primary outcomes

  1. overall survival

    Time frame: during the study conduct

Secondary outcomes

  1. adverse events of induction chemoradiotherapy

    Time frame: during the study conduct

  2. chemotherapy after chemoradiotherapy

    Time frame: during the study conduct

  3. late radiation morbidity

    Time frame: during the study conduct

  4. serious adverse event

    Time frame: during the study conduct

  5. progression-free survival

    Time frame: during the study conduct

07

Study locations

37 sites
  • Aichi Cancer Center Hospital
    Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi 464-8681, Japan
  • Aichi Cancer Center,Aichi Hospital
    Okazaki,Kake-machi,Kuriyado,18, Aichi 444-0011, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi,Kashiwanoha,6-5-1, Chiba 277-8577, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama,Horinouchi,13, Ehime 790-0007, Japan
  • Kyushu University Hospital
    Higashi-ku,Maidashi,3-1-1, Fukuoka 812-8582, Japan
  • Gifu Municipal Hospital
    Gifu,Kashima-cho,7-1, Gifu 500-8323, Japan
  • Gunma Prefectural Cancer Center
    Ota,Takabayashi-nishi-cho,617-1, Gunma 373-8550, Japan
  • National Nishigunma Hospital
    Shibukawa,Kanai,2854, Gunma 377-8511, Japan
  • National Hospital Organization, Dohoku National Hospital
    Asahikawa,Hanasaki,7-4048, Hokkaido 070-8644, Japan
  • National Hospital Organization Hokkaido Cancer Center
    Sapporo,Shiroishi-ku,Kikusui,4-2-3-54, Hokkaido 003-0804, Japan
  • Hyogo Medical Center for Adults
    Akashi,Kitaouji-cho,13-70, Hyogo 673-8558, Japan
  • Kobe City General Hospital
    Kobe,Chuo-ku,Minatojimanakamachi,4-6, Hyogo 650-0046, Japan
  • Hyogo College of Medicine
    Nishinomiya,Mukogawa-cho,1-1, Hyogo 663-8501, Japan
  • Ibaraki Kenritsu Chuo Hospital & Cancer Center
    Nishi-ibarakigun,Tomobemachi,Koibuchi,6528, Ibaraki 309-1793, Japan
  • Kanagawa Cancer Center
    Yokohama,Asahi-ku,Nakao,1-1-2, Kanagawa 241-0815, Japan
  • Yokohama Mucipical Citizen's Hospital
    Yokohama,Hodogaya-ku,Okazawa-cho,56, Kanagawa 240-8555, Japan
  • Kumamoto Regional Medical Center Hospital
    Kumamoto,Honjo,5-16-10, Kumamoto 860-0811, Japan
  • Tohoku University Hospital
    Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi 980-0874, Japan
  • Niigata Cancer Center Hospital
    Niigata,Kawagishi-cho,2-15-3, Niigata 951-8566, Japan
  • Okayama University Hospital
    Okayama,Shikata-cho,2-5-1, Okayama 700-8558, Japan
  • Osaka Prefectural Medical Center for Respiratory and Allergic Disease
    Habikino,Habikino,3-7-1, Osaka 583-8588, Japan
  • Rinku General Medical Center
    Izumisano,rinku-ohrai-kita,2-23, Osaka 598-0048, Japan
  • Graduate School of Medicine, Osaka City University
    Osaka,Abeno-ku,Asahi-machi,1-5-7, Osaka 545-0051, Japan
  • Osaka Medical Center for Cancer and Cardiovascular Diseases
    Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka 537-8511, Japan
  • Osaka City General Hospital
    Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22, Osaka 534-0021, Japan
  • Osaka General Medical Center
    Osaka,Sumiyoshi-ku,Bandai-higashi,3-1-56, Osaka 558-8558, Japan
  • Kinki University School of Medicine
    Osaka-Sayama,Ohno-higashi,377-2, Osaka 589-8511, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Sakai,Nagasone,1180, Osaka 591-8555, Japan
  • National Hospital Organization Toneyama National Hospital
    Toyonaka,Toneyama,5-1-1, Osaka 560-8552, Japan
  • Saitama Cancer Center
    Kita-adachi,Ina,Komuro,818, Saitama 362-0806, Japan
  • Sizuoka Cancer Center
    Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007, Shizuoka 411-8777, Japan
  • Tochigi Cancer Center
    Utsunomiya,Yohnan,4-9-13, Tochigi 320-0834, Japan
  • National Cancer Center Hospital
    Chuo-ku,Tsukiji,5-1-1, Tokyo 104-0045, Japan
  • Cancer Institute Hospital
    Koto-ku,Ariake,3-10-6, Tokyo 135-8550, Japan
  • Toranomon Hospital
    Minato-ku,Toranomon,2-2-2, Tokyo 105-8470, Japan
  • International Medical Center of Japan
    Shinjuku-ku,Toyama,1-21-1, Tokyo 162-8655, Japan
  • Yamagata Prefectural Central Hospital
    Yamagata,Aoyagi,1800, Yamagata 990-2292, Japan
08

References and documents

Publications

  • Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T; Japan Clinical Oncology Group. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3. PubMed 24309370 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2005
First posted
Sep 5, 2005
Start
Sep 2002
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00144989
Lead sponsor
Haruhiko Fukuda
Collaborators
Ministry of Health, Labour and Welfare, Japan
Responsible party
Haruhiko Fukuda (JCOG Data Center, Japan Clinical Oncology Group) — Sponsor-investigator
First posted
Sep 5, 2005
Start date
Sep 2002
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Sep 22, 2016

Study contacts

Yutaka Nishiwaki, MD
study chair · National Cancer Center Hospital East

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion